Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLIHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 19.16 0.00%
DNLI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.06B
- EPS (TTM)
- -$2.84
- Dividend yield
- None
- 52-week range
- 13.75 – 27.30
- Day range
- 18.89 – 19.43
- Volume / Avg
- 1.31M / 1.61M
- Beta
- —
- Shares outstanding
- 159.85M
- Next earnings
- Nov 5, 2026
52-week range
DNLI stock today
Denali Therapeutics (DNLI) closed at $19.16 on Oct 7, down 0.62% (-$0.12), versus the S&P 500's 0.22% decline. Shares are 29.8% below their 52-week high of $27.30, set on Jul 9, 2026 and 39.3% above the 52-week low of $13.75, in the middle of the past year's range. DNLI is up 16.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 28.6%.
Denali Therapeutics has posted a net loss over the last twelve months (EPS of -$2.84), so its P/E ratio is not meaningful. Denali Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Denali Therapeutics
Company profileDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Ryan J. Watts Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 503
- IPO year
- 2017
- Website
- denalitherapeutics.com
Analyst forecast
ForecastConsensus (20 analysts)
strong_buy
Avg. price target
$36.06+88.20%
- Strong buy 2
- Buy 17
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.67
Denali Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs DNLI |
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs DNLI |
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs DNLI |
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs DNLI |
| CELCCelcuity Inc. | 65.78 | -7.68% | $3.22B | vs DNLI |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs DNLI |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs DNLI |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs DNLI |
Indexes, lists and sector
Appears in lists
Denali Therapeutics stock FAQ
What is Denali Therapeutics's stock price today?
DNLI last traded at $19.16 as of Oct 7, 4:00 PM EDT, down 0.62% on the day. Prices are delayed at least 15 minutes.
When is Denali Therapeutics's next earnings date?
Denali Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.67.
Who is Denali Therapeutics's CEO?
Dr. Ryan J. Watts Ph.D. is the chief executive officer of Denali Therapeutics Inc., which has about 503 employees.
What is the DNLI 52-week high?
The 52-week high for DNLI is $27.30 and the 52-week low is $13.75. The stock is currently 29.8% below its high.